DK3365373T3 - Bindingsmolekyler, der hæmmer cancervækst - Google Patents
Bindingsmolekyler, der hæmmer cancervækst Download PDFInfo
- Publication number
- DK3365373T3 DK3365373T3 DK16794080.8T DK16794080T DK3365373T3 DK 3365373 T3 DK3365373 T3 DK 3365373T3 DK 16794080 T DK16794080 T DK 16794080T DK 3365373 T3 DK3365373 T3 DK 3365373T3
- Authority
- DK
- Denmark
- Prior art keywords
- binding molecules
- cancer growth
- inhibit cancer
- inhibit
- growth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15191343 | 2015-10-23 | ||
EP16168647 | 2016-05-06 | ||
PCT/NL2016/050726 WO2017069628A2 (en) | 2015-10-23 | 2016-10-21 | Binding molecules that inhibit cancer growth |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3365373T3 true DK3365373T3 (da) | 2021-04-06 |
Family
ID=57190021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16794080.8T DK3365373T3 (da) | 2015-10-23 | 2016-10-21 | Bindingsmolekyler, der hæmmer cancervækst |
Country Status (26)
Country | Link |
---|---|
US (1) | US11939394B2 (da) |
EP (2) | EP3912998A3 (da) |
JP (3) | JP7296728B2 (da) |
KR (1) | KR20180100305A (da) |
CN (2) | CN108602888B (da) |
AU (2) | AU2016340764B2 (da) |
BR (1) | BR112018008068A2 (da) |
CA (1) | CA3002957A1 (da) |
CY (1) | CY1124108T1 (da) |
DK (1) | DK3365373T3 (da) |
EA (1) | EA201890866A1 (da) |
ES (1) | ES2865482T3 (da) |
HK (1) | HK1253914A1 (da) |
HR (1) | HRP20210483T1 (da) |
HU (1) | HUE055222T2 (da) |
LT (1) | LT3365373T (da) |
MA (2) | MA54760A (da) |
MD (1) | MD3365373T2 (da) |
MX (2) | MX2018004988A (da) |
NZ (1) | NZ742290A (da) |
PL (1) | PL3365373T3 (da) |
RS (1) | RS61800B1 (da) |
SG (1) | SG11201803359VA (da) |
SI (1) | SI3365373T1 (da) |
WO (1) | WO2017069628A2 (da) |
ZA (1) | ZA201802758B (da) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3110846B1 (en) | 2014-02-28 | 2020-08-19 | Merus N.V. | Antibodies that bind egfr and erbb3 |
CA2944649C (en) * | 2014-04-04 | 2022-06-21 | Bionomics, Inc. | Humanized antibodies that bind lgr5 |
JP7296728B2 (ja) | 2015-10-23 | 2023-06-23 | メルス ナムローゼ フェンノートシャップ | 癌の成長を抑制する結合分子 |
WO2017161414A1 (en) | 2016-03-22 | 2017-09-28 | Bionomics Limited | Administration of an anti-lgr5 monoclonal antibody |
CA3049661A1 (en) * | 2017-01-11 | 2018-07-19 | The Board Of Trustees Of The Leland Stanford Junior University | R-spondin (rspo) surrogate molecules |
JP7305543B2 (ja) | 2017-01-26 | 2023-07-10 | スロゼン オペレーティング, インコーポレイテッド | 組織特異的Wntシグナル増強分子およびその使用 |
AU2018246873B2 (en) | 2017-03-31 | 2021-05-06 | Merus N.V. | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene |
TW201920275A (zh) * | 2017-07-06 | 2019-06-01 | 荷蘭商米樂斯股份有限公司 | 藉由細胞表現之調控生物活性的抗體 |
CN111094348A (zh) | 2017-07-06 | 2020-05-01 | 美勒斯公司 | 双特异性抗pd1-抗tim3抗体 |
CA3072404A1 (en) | 2017-08-09 | 2019-02-14 | Merus N.V. | Antibodies that bind egfr and cmet |
SG11202009036YA (en) * | 2018-03-30 | 2020-10-29 | Merus Nv | Multivalent antibody |
CA3104868A1 (en) * | 2018-07-09 | 2020-01-16 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses thereof |
US20220041753A1 (en) * | 2018-12-27 | 2022-02-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Bispecific antibody for membrane clearance of target receptors |
US20220073649A1 (en) * | 2018-12-31 | 2022-03-10 | Merus N.V. | Mixed binding domains |
US20220380440A1 (en) | 2018-12-31 | 2022-12-01 | Merus N.V. | Truncated multivalent multimers |
CN114426578A (zh) * | 2019-02-14 | 2022-05-03 | 美勒斯公司 | 结合egfr、her2及her3的结合部分的组合 |
US11459391B2 (en) | 2019-02-26 | 2022-10-04 | Janssen Biotech, Inc. | Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies |
TW202102544A (zh) * | 2019-04-04 | 2021-01-16 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
WO2020230091A1 (en) | 2019-05-14 | 2020-11-19 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
MX2022002096A (es) * | 2019-08-19 | 2022-03-17 | Merus Nv | Tratamiento del cancer con una combinacion de un anticuerpo que se une al receptor 5 acoplado a la proteina g que contiene repeticiones ricas en leucina (lgr5) y al receptor del factor de crecimiento epidermico (egfr) y un inhibidor de topoisomerasa i. |
AU2020376928A1 (en) * | 2019-11-01 | 2022-05-19 | The Regents Of The University Of California | Degradation of surface proteins using bispecific binding agent |
CN115803345A (zh) * | 2020-03-05 | 2023-03-14 | Umc乌得勒支控股有限公司 | 靶向蛋白质降解的膜泛素连接酶 |
CN115698067A (zh) * | 2020-04-24 | 2023-02-03 | 美勒斯公司 | 使用结合lgr5及egfr的抗体的癌症治疗 |
JP2023532431A (ja) * | 2020-06-18 | 2023-07-28 | ユーエムセー・ユトレヒト・ホールディング・ベー・フェー | 標的-e3リガーゼの有効な組合せのスクリーニング法 |
CN113862326A (zh) * | 2020-09-08 | 2021-12-31 | 复旦大学 | KREMEN1和/或ASGR1作为药物靶点在治疗SARS-CoV-2感染中的应用 |
TW202237656A (zh) | 2020-12-15 | 2022-10-01 | 荷蘭商美勒斯公司 | 利用結合lgr5與egfr之抗體治療癌症 |
US20240058444A1 (en) * | 2020-12-18 | 2024-02-22 | Merus N.V. | Antibody composition |
CN114853889B (zh) * | 2021-02-03 | 2024-03-01 | 中国科学院动物研究所 | 针对人gpr48的单克隆抗体及其应用 |
CN113307882B (zh) * | 2021-05-12 | 2022-12-20 | 东北大学 | 靶向治疗Rspo过度激活导致的结直肠癌的融合蛋白SZ1及其偶联纳米药物 |
TW202321309A (zh) | 2021-10-06 | 2023-06-01 | 荷蘭商美勒斯公司 | 使用至少結合egfr之抗體治療免疫檢查點抑制劑治療之具高egfr表現的癌症 |
CN117567628A (zh) * | 2023-03-07 | 2024-02-20 | 四川尚锐生物医药有限公司 | 一种单克隆抗体或其抗原结合片段及其抗肿瘤的用途 |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
NZ226694A (en) | 1987-10-28 | 1994-04-27 | Oncogen | Human immunoglobulin produced by recombinant dna techniques |
US5151504A (en) | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
EP0523949B1 (en) | 1991-07-15 | 2003-06-25 | The Wellcome Foundation Limited | Production of antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
DE29706518U1 (de) | 1997-04-11 | 1997-05-22 | Missel Gmbh & Co E | Trägersystem für Bade-, Dusch- oder Whirlwannen |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
ES2246069T3 (es) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos. |
ATE447617T1 (de) | 1999-04-15 | 2009-11-15 | Crucell Holland Bv | Verwendung von rekombinanten proteinen in menschlichen zellen |
DE29915950U1 (de) | 1999-09-10 | 1999-12-30 | Cmw Automation Gmbh | Vorrichtung zum Elektrolytbefüllen der Zellen eines Akkumulators |
US20070111201A1 (en) | 2001-04-30 | 2007-05-17 | Benjamin Doranz | Reverse transfection of cell arrays for structural and functional analyses of proteins |
SG143066A1 (en) | 2001-07-04 | 2008-06-27 | Chromagenics Bv | Dna sequences comprising gene transcription regulatory qualities and methods for detecting and using such dna sequences |
US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
EP1510943A4 (en) | 2002-05-31 | 2007-05-09 | Celestar Lexico Sciences Inc | INTERACTION PREDICTION DEVICE |
DK2314629T4 (da) | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
MXPA05006724A (es) | 2003-01-07 | 2005-09-08 | Symphogen As | Metodo para producir proteinas policlonales recombinantes. |
CA2526284C (en) | 2003-06-25 | 2014-11-18 | Crucell Holland B.V. | Binding molecules for the treatment of myeloid cell malignancies |
EA010350B1 (ru) | 2004-06-03 | 2008-08-29 | Новиммун С.А. | Антитела против cd3 и способы их применения |
CA2577082A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP1853309A4 (en) | 2005-02-23 | 2008-10-22 | Merrimack Pharmaceuticals Inc | BISPECIFIC BINDER FOR MODULATING BIOLOGICAL ACTIVITY |
US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー/エス | 二重特異性抗体の生産 |
EP2059533B1 (en) | 2006-08-30 | 2012-11-14 | Genentech, Inc. | Multispecific antibodies |
US8290739B2 (en) | 2006-10-20 | 2012-10-16 | Amfit, Inc. | Method for determining relative mobility of regions of an object |
EP2091975A4 (en) | 2006-11-21 | 2013-05-22 | Univ California | ANTIBODIES TO THE EGFR FAMILY, BICE-SPECIFIC ANTIBODIES TO THE EGFR FAMILY AND METHOD FOR THEIR USE |
RS53042B (en) | 2007-02-16 | 2014-04-30 | Merrimack Pharmaceuticals Inc. | ANTIBODIES AGAINST ERBB3 AND THEIR USES |
CA2681974C (en) | 2007-03-29 | 2019-12-31 | Genmab A/S | Bispecific antibodies and methods for production thereof |
US20100183615A1 (en) | 2007-04-03 | 2010-07-22 | Micromet Ag | Cross-species-specific bispecific binders |
US7705103B2 (en) | 2007-06-22 | 2010-04-27 | 3M Innovative Properties Company | Polydiorganosiloxane polyoxamide copolymers |
HUE027154T2 (en) | 2007-07-02 | 2016-08-29 | Oncomed Pharm Inc | Preparations and procedures for the treatment and diagnosis of cancer |
US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
US10416162B2 (en) | 2007-12-20 | 2019-09-17 | Monogram Biosciences, Inc. | Her2 diagnostic methods |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
EP2245571B1 (en) | 2008-02-05 | 2019-04-10 | Zymeworks Inc. | Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics |
PT2147594E (pt) | 2008-06-27 | 2014-02-17 | Merus B V | Mamíferos não humanos que produzem anticorpos |
WO2010022736A2 (en) | 2008-08-29 | 2010-03-04 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
CN102460152B (zh) | 2009-01-15 | 2014-11-26 | 美国控股实验室公司 | 通过测量Her-3确定患者反应的方法 |
CN104262483A (zh) | 2009-01-26 | 2015-01-07 | 根马布股份公司 | 用于生成抗体混合物的方法 |
CN102356092B (zh) | 2009-03-20 | 2014-11-05 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
EP2445936A1 (en) | 2009-06-26 | 2012-05-02 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
CA2771744A1 (en) | 2009-08-21 | 2011-02-24 | Merrimack Pharmaceuticals, Inc. | Antibodies against the ectodomain of erbb3 and uses thereof |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
EP2496598B1 (en) | 2009-11-04 | 2017-08-02 | Affibody AB | Her3 binding polypeptides |
EP2501817B2 (en) | 2010-02-08 | 2021-04-21 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
CN103261220B (zh) | 2010-08-16 | 2016-06-15 | 诺夫免疫股份有限公司 | 用于生成多特异性和多价抗体的方法 |
PT2606070T (pt) | 2010-08-20 | 2017-03-31 | Novartis Ag | Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3) |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
RU2604490C2 (ru) | 2010-11-05 | 2016-12-10 | Займворкс Инк. | ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ |
AU2012222094A1 (en) | 2011-02-24 | 2013-10-10 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-ErbB3 agents |
CN103429262A (zh) | 2011-03-15 | 2013-12-04 | 梅里麦克制药股份有限公司 | 克服对erbb途径抑制剂的抗性 |
SG10201602371VA (en) | 2011-03-25 | 2016-04-28 | Glenmark Pharmaceuticals Sa | Hetero-dimeric immunoglobulins |
GB201106395D0 (en) * | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
DK2707391T3 (da) | 2011-05-13 | 2018-02-05 | Gamamabs Pharma | Antistoffer mod her3 |
KR20140033152A (ko) | 2011-06-20 | 2014-03-17 | 교와 핫꼬 기린 가부시키가이샤 | 항erbB3 항체 |
EP2731625B1 (en) * | 2011-07-15 | 2018-04-18 | OncoMed Pharmaceuticals, Inc. | Rspo binding agents and uses thereof |
US9567827B2 (en) | 2013-07-15 | 2017-02-14 | Downhole Technology, Llc | Downhole tool and method of use |
CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
US8791244B2 (en) | 2011-09-30 | 2014-07-29 | Regeneron Pharmaceuticals, Inc. | Anti-ErbB3 antibodies and uses thereof |
DK2797957T3 (da) | 2011-11-23 | 2019-09-23 | Medimmune Llc | Bindingsmolekyler specifikke for her3 og anvendelser deraf |
BR112014013495A2 (pt) | 2011-12-05 | 2017-06-13 | Novartis Ag | anticorpos para o receptor 3 do fator de crescimento epidérmico (her3) direcionados para o domínio iii e domíniuo iv de her3 |
MX362521B (es) | 2011-12-05 | 2019-01-22 | Novartis Ag | Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3). |
CN102448183A (zh) | 2012-01-18 | 2012-05-09 | 大唐移动通信设备有限公司 | 一种Uu接口重配置方法及设备 |
EP2823270B1 (en) | 2012-03-09 | 2022-05-04 | Promega Corporation | pH SENSORS |
AU2013240261A1 (en) | 2012-03-27 | 2014-09-18 | Genentech, Inc. | Diagnosis and treatments relating to HER3 inhibitors |
AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
PT2838918T (pt) | 2012-04-20 | 2019-08-23 | Merus Nv | Métodos e meios para a produção de moléculas heterrodiméricas do tipo ig |
TWI641619B (zh) | 2012-06-25 | 2018-11-21 | 美商再生元醫藥公司 | 抗-egfr抗體及其用途 |
US10358492B2 (en) | 2012-09-27 | 2019-07-23 | Merus N.V. | Bispecific IgG antibodies as T cell engagers |
CA2883264A1 (en) | 2012-10-15 | 2014-04-24 | Universitat Zurich Prorektorat Mnw | Bispecific her2 ligands for cancer therapy |
HUE052548T2 (hu) | 2012-11-21 | 2021-05-28 | Janssen Biotech Inc | Bispecifikus EGFR/C-MET-ellenanyagok |
US9359444B2 (en) | 2013-02-04 | 2016-06-07 | Oncomed Pharmaceuticals Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
WO2014159580A1 (en) * | 2013-03-14 | 2014-10-02 | Oncomed Pharmaceuticals, Inc. | Met-binding agents and uses thereof |
EP2981828A1 (en) | 2013-04-05 | 2016-02-10 | Laboratory Corporation of America Holdings | Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation |
EP2994164B1 (en) | 2013-05-08 | 2020-08-05 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
US9879081B2 (en) | 2013-06-25 | 2018-01-30 | Samsung Electronics Co., Ltd. | Protein complex, bispecific antibody including the protein complex, and method of preparation thereof |
US9551208B2 (en) | 2013-08-26 | 2017-01-24 | Halliburton Energy Services, Inc. | Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation |
US10519247B2 (en) | 2013-11-01 | 2019-12-31 | Board Of Regents,The University Of Texas System | Targeting HER2 and HER3 with bispecific antibodies in cancerous cells |
IL301147A (en) | 2014-02-28 | 2023-05-01 | Merus Nv | An antibody that binds to ErbB-2 and ErbB-3 |
EP3110846B1 (en) | 2014-02-28 | 2020-08-19 | Merus N.V. | Antibodies that bind egfr and erbb3 |
CN106459199B (zh) * | 2014-03-11 | 2021-01-01 | 瑞泽恩制药公司 | 抗-egfrviii抗体及其用途 |
CA2944649C (en) | 2014-04-04 | 2022-06-21 | Bionomics, Inc. | Humanized antibodies that bind lgr5 |
MA41123A (fr) | 2014-12-02 | 2017-10-10 | Oncomed Pharm Inc | Polythérapie pour le traitement du cancer |
US10383945B2 (en) * | 2015-02-18 | 2019-08-20 | The United States of America as Represented by the Department of Verterans Affairs | Methods for DNA-dependent targeting of a cell permeant antibody |
AU2016293942B2 (en) | 2015-07-10 | 2022-06-16 | Merus N.V. | Human CD3 binding antibody |
JP7296728B2 (ja) | 2015-10-23 | 2023-06-23 | メルス ナムローゼ フェンノートシャップ | 癌の成長を抑制する結合分子 |
EP3393494A1 (en) * | 2015-12-22 | 2018-10-31 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
AU2018246873B2 (en) | 2017-03-31 | 2021-05-06 | Merus N.V. | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene |
WO2018182420A1 (en) | 2017-03-31 | 2018-10-04 | Merus N.V. | Antibodies for the treatment of erbb-2/erbb-3 positive tumors |
BR112019024230A2 (pt) | 2017-05-17 | 2020-06-09 | Merus N.V. | combinação de um anticorpo bispecífico erbb-2 / erbb-3 com terapia endócrina para câncer de mama |
CA3072404A1 (en) | 2017-08-09 | 2019-02-14 | Merus N.V. | Antibodies that bind egfr and cmet |
MX2021007848A (es) * | 2018-12-27 | 2021-10-26 | Gigagen Inc | Proteinas de union a anti-ctla-4 y metodos de uso de las mismas. |
-
2016
- 2016-10-21 JP JP2018540363A patent/JP7296728B2/ja active Active
- 2016-10-21 CN CN201680065283.5A patent/CN108602888B/zh active Active
- 2016-10-21 MA MA054760A patent/MA54760A/fr unknown
- 2016-10-21 ES ES16794080T patent/ES2865482T3/es active Active
- 2016-10-21 PL PL16794080T patent/PL3365373T3/pl unknown
- 2016-10-21 EP EP21161572.9A patent/EP3912998A3/en active Pending
- 2016-10-21 NZ NZ74229016A patent/NZ742290A/en unknown
- 2016-10-21 SI SI201631138T patent/SI3365373T1/sl unknown
- 2016-10-21 BR BR112018008068A patent/BR112018008068A2/pt active Search and Examination
- 2016-10-21 HU HUE16794080A patent/HUE055222T2/hu unknown
- 2016-10-21 DK DK16794080.8T patent/DK3365373T3/da active
- 2016-10-21 AU AU2016340764A patent/AU2016340764B2/en active Active
- 2016-10-21 US US15/770,317 patent/US11939394B2/en active Active
- 2016-10-21 LT LTEP16794080.8T patent/LT3365373T/lt unknown
- 2016-10-21 EA EA201890866A patent/EA201890866A1/ru unknown
- 2016-10-21 KR KR1020187014570A patent/KR20180100305A/ko not_active Application Discontinuation
- 2016-10-21 MD MDE20180831T patent/MD3365373T2/ro unknown
- 2016-10-21 WO PCT/NL2016/050726 patent/WO2017069628A2/en active Application Filing
- 2016-10-21 EP EP16794080.8A patent/EP3365373B1/en active Active
- 2016-10-21 MA MA45517A patent/MA45517B1/fr unknown
- 2016-10-21 SG SG11201803359VA patent/SG11201803359VA/en unknown
- 2016-10-21 CN CN202211112405.5A patent/CN115925944A/zh active Pending
- 2016-10-21 CA CA3002957A patent/CA3002957A1/en active Pending
- 2016-10-21 MX MX2018004988A patent/MX2018004988A/es unknown
- 2016-10-21 RS RS20210479A patent/RS61800B1/sr unknown
-
2018
- 2018-04-23 MX MX2022000302A patent/MX2022000302A/es unknown
- 2018-04-25 ZA ZA2018/02758A patent/ZA201802758B/en unknown
- 2018-10-12 HK HK18113062.6A patent/HK1253914A1/zh unknown
-
2021
- 2021-03-24 HR HRP20210483TT patent/HRP20210483T1/hr unknown
- 2021-04-19 CY CY20211100338T patent/CY1124108T1/el unknown
- 2021-11-05 JP JP2021181173A patent/JP2023008754A/ja active Pending
-
2023
- 2023-08-31 AU AU2023222928A patent/AU2023222928A1/en active Pending
- 2023-11-29 JP JP2023201785A patent/JP2024023445A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3365373T3 (da) | Bindingsmolekyler, der hæmmer cancervækst | |
FIC20230006I1 (fi) | Vutrisiraani | |
DK3411065T3 (da) | Clec9a-bindingsmidler | |
MA43259A (fr) | Liants ctla4 | |
DK3327224T3 (da) | Bindemaskine | |
GB201521858D0 (en) | Small molecules | |
DK3580211T3 (da) | 2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamider til behandling af cancer | |
DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
DK3326921T3 (da) | Bindemaskine | |
DK3240801T3 (da) | Kombinationstumorimmunterapi | |
ES2969322T3 (es) | Aglutinantes | |
GB201612520D0 (en) | Binding molecules | |
IL277261A (en) | Low molecular weight compounds for cancer treatment | |
BR112016022698A2 (pt) | filtrado inteligente para o fortalecimento de formações. | |
DK3105250T3 (da) | Multispecifikke iga-bindingsmolekyler | |
DK3242685T3 (da) | Cxcr4-bindende molekyler | |
DE102016117105A8 (de) | Antenneneinrichtung | |
ITUA20164548A1 (it) | Skateboard perfezionato. | |
DE112018000104A5 (de) | Ablage | |
ES1150114Y (es) | Abarcón. | |
MA42609A (fr) | Polythérapie contre le cancer | |
DK3606953T3 (da) | Fgfr3-bindende molekyler | |
IL258866A (en) | Binding molecules that inhibit cancer growth | |
PT3365373T (pt) | Moléculas de ligação que inibem o crescimento do cancro | |
ES1166158Y (es) | Tapa-colador para ollas exprés |